PhRMA’s “I’m In” Campaign Looks To Connect Minorities To Studies
This article was originally published in The Pink Sheet Daily
Extension of the Clinical Trial Engagement Network is aimed at increased diversity in clinical trials, which is becoming increasingly important as more drugs are targeted at specific groups.
You may also be interested in...
Should US FDA Refuse Approval If Women Under-Represented In Clinical Trials?
Idea suggested during 'Great Debate,' but agency official says no adlibbing is allowed in the regulations.
Pricing, Pediatrics, Pot: 21st Century Cures Amendments
Committee members didn’t even vote on any amendments besides the manager’s package, but proposals floated and withdrawn offer glimpse at potential fights to come.
Clinical Trial Diversity: ‘How Much More Evidence Do We Need To Move Forward?’
FDA seeks research ideas and plans to include demographic subgroup analyses in review templates as some stakeholders call for bolder action to change how companies conduct clinical trials.